



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,915	12/23/2004	Kiichiro Yano	053-466-0391	7057
23428 7590 12/16/2009 FOLEY AND LARDNER LLP SUITE 500 3000 K STREET NW WASHINGTON, DC 20007				
EXAMINER				
CLARK, AMY LYNN				
ART UNIT		PAPER NUMBER		
1655				
MAIL DATE		DELIVERY MODE		
12/16/2009		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/518,915

**Applicant(s)**

YANO ET AL.

**Examiner**

Amy L. Clark

**Art Unit**

1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 08 September 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 4, 6, 8-13 and 15-25 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 4, 6, 8-13 and 15-25 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB-06)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION**

***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(c), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(c) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/08/2009 has been entered.

Acknowledgment is made of the receipt and entry of the amendment filed on 09/08/2009 with the amendment of claims 4, 6, 8, 10-13 and 15-19.

Any rejection found in the previous Office Action and not repeated herein has been withdrawn based upon Applicants' amendments to the claims.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

**Claims 4, 6, 8-13 and 15-25 are currently being examined on the merits.**

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 4, 6, 8-13 and 15-25 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of treating skin in a subject comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. inermis Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. ma-yuen Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, does not reasonably provide enablement for a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. inermis Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. ma-yuen Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, nor does the specification provide enablement for a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. inermis Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract, coicis semen (*Coix lacryma-jobi* Linne var. ma-yuen Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, wherein the method of inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject. The specification does not enable any person

skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Enablement is considered in view of the *Wands* factors (MPEP 2164.01(A)). These include: nature of the invention, breadth of the claims, guidance of the specification, the existence of working examples, state of the art predictability of the art and the amount of experimentation necessary. All of the *Wands* factors have been considered with regard to the instant claims, with the most relevant factors discussed below.

*Nature of the Invention:* Claim 4 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract and claim 12 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract, coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, wherein the method of inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject.

The nature of the invention is complex in that claim 4 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs

consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract and claim 12 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract, coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, wherein the method of inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject.

*Breadth of the Claims:* The claims are broad in that the claims are drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract and claim 12 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract, coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, wherein the method of inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject. The complex nature of the subject matter of this invention is greatly exacerbated by the breadth of the claims.

*Guidance of the Specification and Existence of Working Examples:* The specification describes two *in vitro* experiments comprising undisclosed types of extracts of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder), roman chamomile (*Anthemis nobilis* Linne), coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf), and silk (*Bombyx mori* Linnacus). The first Experiment involves a luciferase assay for screening TSP-1 inducers and Experiment 2 involves the screening of an apoptosis inducer. Applicants provide two Figures that allegedly show activity of each extract studied. However, the data is confusing in that it is not clear what Applicants are measuring, particularly with regards to Experiment 2, where the results appear to be the same as the TSP-1 itself. The description of both experiments is lacking details, like how the TSP-1 activity was measured in the luciferase assay, nor is there a control using a known TSP-1 inducer to demonstrate activity. Furthermore, Applicants do not provide any indication of how they have made each extract or what the extracts are. Finally, there are no experiments conducted to demonstrate a correlation between TSP-1 activity or luciferase and inhibition of wrinkles caused by any mechanism, particularly photoaging.

The specification envisions that by administering a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnacus) extract that the composition will inhibit angiogenesis in a subject in need thereof and that inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject.

However, no working examples are provided with regard to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a

composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract and claim 12 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract, coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, wherein the method of inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject.

Applicants have not provided adequate studies to demonstrate that these ingredients, either on their own or in combination, have the claimed functional effects.

*Predictability and State of the Art:* The state of the art at the time the invention was made was unpredictable and underdeveloped.

Filleur et al. (X1, "In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects". *Genes Dev.* 2001 June 1; 15(11): 1373–1382) teaches a method of using TSP-1 in an *in vitro* and *in vivo* study to demonstrate its effect on angiogenesis. Filleur further teaches using TSP-1 in a cell culture involving luciferase, but demonstrate that assays involving luciferase do not already contain TSP-1.

In Applicants' specification, it appears that Applicants are stating that by employing da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk



(*Bombyx mori* Linnaeus) extract in an in vitro assay that these extracts induce TSP-1 and increase its function.. However, the assay employed does not contain TSP-1, and if it does, it is not adequately described, so it is unclear as to how Applicants arrive at the assumption that these extracts have this effect.

Thus, while the claim-designated method may be useful for providing such an effect, Applicant does not disclose a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract and claim 12 is drawn to a method of inhibiting angiogenesis in a subject in need thereof, comprising applying onto the skin of said subject a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract, coicis semen (*Coix lacryma-jobi* Linne var. *ma-yuen* Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract, wherein the method of inhibiting angiogenesis inhibits wrinkles caused by photoaging of the skin of said subject.

*Amount of Experimentation Necessary:* The quantity of experimentation necessary to carry out the claimed invention is high, as the skilled artisan could not rely on the prior art or instant specification to teach how to use a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjuzuba* Miller var. *inermis* Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-*

*jobi* Linne var. ma-yuen Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract for inhibiting angiogenesis and inhibiting wrinkles caused by photoaging.. In order to carry out the claimed invention, one of ordinary skill in the art would have to a composition comprising at least one active ingredient selected from a group of crude drugs consisting of da zao (*Zizyphusjujuba* Miller var. inermis Rehder) extract, roman chamomile (*Anthemis nobilis* Linne) extract coicis semen (*Coix lacryma-jobi* Linne var. ma-yuen Stapf) extract, and silk (*Bombyx mori* Linnaeus) extract that can be administered in a therapeutically effective dose with an acceptable level of side-effects.

In view of the breadth of the claims and the lack of guidance provided by the specification as well as the unpredictability of the art, the skilled artisan would have required an undue amount of experimentation to make and/or use the claimed invention. Therefore, claims 4, 6, 8-13 and 15-25 are not considered to be fully enabled by the instant specification.

Please note that the rejections below are based upon what Applicants are enabled for.

#### ***Claim Rejections - 35 USC § 102***

Claims 4 and 12 remain rejected under 35 U.S.C. 102(b) as being anticipated by Uehara et al. (N1\*, JP 2000-119156, Translation provided in the previous Office Action).

Uehara teaches a method of decreasing pigmentation in a guinea pig brought wherein the pigmentation is induced by irradiation of guinea pig skin with UV-B light comprising administering a composition comprising an extract of coix seed (*Coix lacryma-jobi*) (See

paragraphs 0039 and 0040), which reads on inhibiting photoaging in a subject in need there of and also reads on inhibiting wrinkles caused by photoaging because the composition clearly treats symptoms of photoaging when applied to the skin of a subject. Uehara further teaches a method of preventing skin dullness and pigmentation comprising administering a composition comprising coix-seed extract in an amount of 0.01% or a composition comprising chamomile extract (See the Examples).

Claims 4, 11, 12 and 18 remain rejected under 35 U.S.C. 102(b) as being anticipated by Garlen et al. (B\*, 4,707,354).

Garlen teaches a method for treating skin comprising covering said skin with a layer of a sunscreen, protectant, moisturizing, dermatological composition consisting essentially of a formulation comprising less than 1 wt % silk powder (See claim 8). Garlen further teaches that the method for administration of such compositions to human skin to provide rehydration and nearly complete screening of cancer-causing actinic radiation (See abstract) and protects mature skin from cell damage and dehydration due to exposure to sunlight (See "Field of the Invention"), which reads on "inhibits photoaging" and "inhibiting wrinkles caused by photoaging", since blocking sunlight inhibits photoaging and inhibits wrinkle formation caused by photoaging.

Therefore, the reference anticipates the claimed subject matter.

***Claim Rejections - 35 USC § 103***

Claims 4, 6, 8-13 and 15-25 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Sei et al. (S\*, JP 2002-128651 A), in view of Andre-Jean et al. (T\*, JP 07-145067 A).

Sei teaches a photoaging inhibitor (See abstract) that has an anti-aging effect and demonstrates a high improvement effect to wrinkles (See paragraph 0077) in the form of a topical composition for administration to the skin comprising ginseng extract in an amount of 0.00001 - 10 mass %, or 0.0001 to 5% (See paragraph 0008), coix seed extract, a seaweed extract (See paragraph 0037), chamomile extract (See paragraph 0012) in an amount of 0.0001 to 3% (See paragraph 0018), silk protein (which is a type of silk extract) and a zizyphi fructus extract (See paragraph 0039). Sei further teaches that the skin care composition is administered, topically, to a mouse and that the skin care composition is administered, *in vitro*, to human skin cells (See Examples paragraphs 0041-0063). Please note that by applying a composition that is capable of inhibiting photoaging leads to inhibition of angiogenesis, since angiogenesis is stimulated by UV exposure. Therefore, the effect of inhibiting angiogenesis would be intrinsic to a photoaging inhibitor.

Andre-Jean teaches a cosmetic composition for treating skin comprising 0.1-15 wt.% hydroglycol extract of alga such as Chlorella (See abstract). Andre-Jean further teaches that the therapeutic method by these cosmetics protects the skin and hair from the exteriors, such as an oxidizer, sunrays, and a staining agent, against the element which does adverse action, maintains the organization of the skin or hair, and aims at improving the quality of the skin (See paragraph 0038), which reads on inhibiting photoaging. Andre-Jean further teaches examples of

administering the cosmetic composition to the skin (See Example 1 beginning with paragraph 0040).

The method of using the referenced composition is not expressly taught as a method of inhibiting wrinkles caused by photoaging. However, the instantly claimed process is a **one-step process** of applying to skin a composition comprising .1-15 wt.% hydroglycol extract of alga such as Chlorella. Thus, the functional effect of protecting keratinous fiber from extrinsic damage is intrinsic to the method of using the composition taught by Andre-Jean particularly since the amount of an extract of chlorella administered to the skin falls within the range claimed by Applicant.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the method taught by Sei by administering a composition comprising da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract, which are all ingredients that have the same functional effect of inhibiting photoaging and inhibiting wrinkles caused by photoaging. Further, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the instantly claimed ingredients of da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract for their known benefit of inhibiting photoaging and inhibiting wrinkles caused by photoaging since each claimed ingredient is well known in the art for the same purpose, as useful for weight loss and for the following reason:

It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been

individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980); *In re Crockett*, 279 F.2d 274, 126 USPQ 186 (CCPA 1960); and *Ex parte Quadranti*, 25 USPQ2d 1071 (Bd. Pat. App. & Inter. 1992). As the court explained in Crockett, the idea of combining them flows logically from their having been individually taught in prior art. Therefore, since each of the references teach that da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract, are useful for inhibiting photoaging and inhibiting wrinkles caused by photoaging, it would have been obvious to combine these ingredients with the expectation that such a combination would be effective for inhibiting photoaging and inhibiting wrinkles caused by photoaging. Thus, combining them flows logically from their having been individually taught in prior art.

From the teachings of the references, it is apparent that one of ordinary skill in the art one would have been motivated to combine da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract to provide a beneficial composition for the expected benefit of inhibiting photoaging and inhibiting wrinkles caused by photoaging because at the time the invention was made, the instantly claimed ingredients da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract were known to be useful for inhibiting photoaging and inhibiting wrinkles caused by photoaging, and since the ingredients and mode of administering the ingredients, which are one and the same as those claimed by Applicants, was known in the art at the time the invention was made. Thus the combined composition of da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract would have been expected to be even more effective for

inhibiting photoaging and inhibiting wrinkles caused by photoaging because the claimed ingredients were all useful for this purpose, as clearly taught by the above references.

Finally, one of ordinary skill in the art would have had a reasonable expectation of success to combine the following ingredients for inhibiting photoaging and inhibiting wrinkles caused by photoaging to gain the benefits of individual components as part of a composition for inhibiting photoaging and inhibiting wrinkles caused by photoaging: da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract, to provide a beneficial composition for the expected benefit of inhibiting photoaging and inhibiting wrinkles caused by photoaging because at the time the invention was made, these ingredients were well known promoting weight loss.

Moreover, it would have been obvious to one of ordinary skill in the art, one would have been motivated and one would have had a reasonable expectation of success at the time the invention was made to modify the referenced composition because it would have been well in the purview of one of ordinary skill in the art practicing the invention to pick and choose a concentration of da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract because at the time the invention was made, da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract were known to be useful for promoting inhibiting photoaging and inhibiting wrinkles caused by photoaging and the references provided herein teach amounts of the ingredients claimed. Therefore, adjusting the amount of da zhao extract, ginseng extract, chamomile extract, chlorella extract, coicis semen extract, and silk extract would have been obvious to enhance the effect of these ingredients. Thus, the claimed invention is no more than the routine optimization of a

result effect variable.

Based upon the beneficial teachings of the cited references, the skill of one of ordinary skill in the art, and absent evidence to the contrary, there would have been a reasonable expectation of success to result in the claimed invention.

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made, especially in the absence of evidence to the contrary.

#### ***Response to Arguments***

Applicants' arguments with regards to the rejection under 35 U.S.C. 102(b) and 103(a) have been carefully considered but are not deemed to be persuasive of error in the rejection.

Applicants argue that claims 4, 12 and 19 recite "a method of inhibiting angiogenesis in a subject in need thereof...", that Uehara teaches a whitening agent comprising coix seed, Garlen teaches a cosmetic product containing silk powder as merely an auxiliary component, Sei teaches using roman chamomile as an anti-inflammatory ingredient and coicis semen as a whitening agent and Andre- Jean teaches a cosmetic composition containing Chlorella as an anti-inflammation reagent. However, all of the prior art references are completely silent regarding activities of the crude drugs for inhibiting angiogenesis.

This is not found persuasive because Applicants are not enabled for "a method of inhibiting angiogenesis in a subject in need thereof...". Furthermore, the ingredients taught in the 102(b) and 103(a) references are present in the amounts claimed by Applicants and are administered in the same way as claimed by Applicants. With regards to the Sei reference, Sei



teaches that the instantly claimed ingredient of silk extract is an active ingredient in the composition. Further, Applicants use open claim language which does not prevent other active ingredients to be present in a composition comprising Applicants' instantly claimed ingredients. Sei expressly teaches "silk protein" in paragraph 0039, which is a type of silk extract, and "zizyphi fructus extract", also in paragraph 0039, which is synonymous with da zao. Applicants are invited to further define their invention by closing the claim language and by further describing the type of extract Applicants' are employing (for example: aqueous, ethanol, hexane, organic, etc.) used in the method, provided they have appropriate support in the specification.

### ***Conclusion***

**No claims are allowed.**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy L. Clark whose telephone number is (571)272-1310. The examiner can normally be reached on Monday to Friday between 8:30am - 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Amy L Clark/  
Examiner, Art Unit 1655